BOWN
Bowen Acquisition Corp9.19
-0.01-0.11%
Nov 25, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
27.52MP/E (TTM)
-Basic EPS (TTM)
-0.22Dividend Yield
0%Recent Filings
8-K
10-Q
Q2 FY2025 results
Bowen Acquisition Corp swung to a $750,303 net income for Q2 ended June 30, 2025, up from $816,754 a year earlier, yet the six-month loss hit $1,289,691 after heavy redemptions slashed the trust from $75.8M to $8.3M. Operating losses narrowed to $76,828 from $125,096 year-over-year, cushioned by $88,405 in trust interest, while a $755,837 fair-value gain on the FPA liability offset minor interest expenses. Cash dwindles to $17,556 amid a $1.9M working capital deficit, with $500,000 in related-party debt and $806,502 FPA liability hanging; the pending merger with Shenzhen Qianzhi BioTechnology awaits regulatory nods. Redemptions fueled the trust drain. Nasdaq delisting looms over low share count.
8-K
Nasdaq delisting threat hits SPAC
Bowen Acquisition Corp faces Nasdaq delisting after failing key listing rules, including a market value of listed securities below $50 million, fewer than 1.1 million publicly held shares, and under 400 total shareholders. Trading halted on July 15, 2025; the SPAC plans to appeal by July 22 to delay suspension set for July 24. It eyes compliance via its pending merger with Shenzhen Qianzhi BioTechnology, yet success remains uncertain. Delisting risks liquidity sharply.
8-K
Nasdaq delisting notice issued
Bowen Acquisition Corp received a Nasdaq notice on July 10, 2025, for failing to maintain at least 1,100,000 publicly held shares under Listing Rule 5450(b)(2)(B). The company must submit a compliance plan by August 25, 2025, potentially earning up to 180 days to fix it. Trading continues uninterrupted under 'BOWN.' No assurance of regaining compliance.
8-K
SPAC deadline extended
Bowen Acquisition Corp's shareholders approved an amendment on July 11, 2025, extending the business combination deadline from July 14 to up to December 14, 2025, in three one-month increments, with 2,184,186 votes for and just 5,548 against. This buys time to close the proposed merger with Shenzhen Qianzhi BioTechnology Co. Ltd. amid ongoing conditions. Yet risks linger if the deal falters.
BAYA
Bayview Acquisition Corp
11.63-0.01
BCAR
D. Boral ARC Acquisition I Corp
10.01-0.01
IBAC
IB Acquisition Corp.
10.45+0.00
QETA
Quetta Acquisition Corporation
11.20-0.05
RIBB
Ribbon Acquisition Corp
10.35+0.01
SOUL
Soulpower Acquisition Corporati
10.13+0.00
TACO
Berto Acquisition Corp.
10.13+0.00
UYSC
UY Scuti Acquisition Corp.
10.22+0.00
WLAC
Willow Lane Acquisition Corp.
11.86+0.45
YHNA
YHN Acquisition I Limited
10.65+0.00